SCHEMBL2651365

SCHEMBL2651365

O=C(O)Cc1ccc(S(=O)(=O)C2CCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 1/20 0.44
CA2 P00918 1/20 0.44
CAMK2A Q9UQM7 1/20 0.44
NAMPT P43490 4/20 0.43
AKR1B1 P15121 1/20 0.42
DDIT3 P35638 1/20 0.42
HTR2A P28223 2/20 0.42
ABCC4 O15439 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
PTGS1 P23219 1/20 0.42
HTT P42858 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TBXA2R P21731 1/20 0.41
CYP2C9 P11712 1/20 0.41
MMP8 P22894 2/20 0.40
MMP13 P45452 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2894511 0.93 CA2 (0.47) MEP1BCA2CAMK2AAKR1B1DDIT3
SCHEMBL5428145 0.78 FFAR4 (0.46) NAMPTAKR1B1HTR2AHTR2CKCNH2
SCHEMBL5464162 0.76 SMN1; SMN2 (0.62) MEP1BNAMPTLMNAGAATSHR
SCHEMBL23000549 0.75 MEP1B (0.43) MEP1BCA2CAMK2AAKR1B1ABCC4
SCHEMBL16799853 0.75 CA2 (0.46) MEP1BCA2CAMK2AAKR1B1ABCC4
SCHEMBL13341421 0.74 MMP9 (0.52) LMNAGAAALDH1A1KDM4EMMP13
SCHEMBL7541817 0.74 HTR2A (0.56) HTR2AGAAALDH1A1KDM4EMMP8
SCHEMBL3714450 0.74 KMT2A (0.53) CA2NAMPTTSHRALDH1A1
SCHEMBL6181601 0.73 DDIT3 (0.37) NAMPTDDIT3HTR2ALMNAALDH1A1
SCHEMBL2669484 0.73 NAMPT (0.38) NAMPTDDIT3HTR2AALDH1A1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168962-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2010-03-31 EP disclosed
EP-1594867-B1 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LTD (GB) 2008-04-09 EP disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed
EP-1594867-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2005-11-16 EP disclosed
US-20040181067-A1 Tri(cyclo) substituted amide compounds OSI PHARMACEUTICALS, INC. 2004-09-16 US disclosed
WO-2004072031-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LIMITED (GB) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181067-A1 Tri(cyclo) substituted amide compounds GPR119, IAPP, SLC5A1 MEP1B 2476/4885CA2 1656/4885CAMK2A 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.